JOUNCE THERAPEUTICS INC (JNCE) Stock Price & Overview
NASDAQ:JNCE • US4811161011
Current stock price
The current stock price of JNCE is 1.88 USD. Today JNCE is down by -2.59%. In the past month the price increased by 0.53%. In the past year, price decreased by -65.76%.
JNCE Key Statistics
- Market Cap
- 98.955M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.99
- Dividend Yield
- N/A
JNCE Stock Performance
JNCE Stock Chart
JNCE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to JNCE. When comparing the yearly performance of all stocks, JNCE turns out to be only a medium performer in the overall market: it outperformed 50.11% of all stocks.
JNCE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JNCE. JNCE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
JNCE Earnings
JNCE Forecast & Estimates
13 analysts have analysed JNCE and the average price target is 1.65 USD. This implies a price decrease of -12.29% is expected in the next year compared to the current price of 1.88.
For the next year, analysts expect an EPS growth of -37.55% and a revenue growth -100% for JNCE
JNCE Groups
Sector & Classification
JNCE Financial Highlights
Over the last trailing twelve months JNCE reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 46.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
JNCE Ownership
JNCE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 362.599B | ||
| AMGN | AMGEN INC | 15.24 | 187.489B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 170.335B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 115.33B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.479B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.4B | ||
| INSM | INSMED INC | N/A | 29.315B | ||
| NTRA | NATERA INC | N/A | 27.677B | ||
| BIIB | BIOGEN INC | 11.29 | 26.631B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 22.979B | ||
| MRNA | MODERNA INC | N/A | 20.292B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.981B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About JNCE
Company Profile
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2017-01-26. The company is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). The company also develops JTX-1484 and JTX-2134 product candidates.
Company Info
IPO: 2017-01-26
JOUNCE THERAPEUTICS INC
780 Memorial Drive
Cambridge MASSACHUSETTS 02139 US
CEO: Richard Murray
Employees: 141
Phone: 18572593840.0
JOUNCE THERAPEUTICS INC / JNCE FAQ
What does JOUNCE THERAPEUTICS INC do?
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2017-01-26. The company is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). The company also develops JTX-1484 and JTX-2134 product candidates.
Can you provide the latest stock price for JOUNCE THERAPEUTICS INC?
The current stock price of JNCE is 1.88 USD. The price decreased by -2.59% in the last trading session.
What is the dividend status of JOUNCE THERAPEUTICS INC?
JNCE does not pay a dividend.
What is the ChartMill rating of JOUNCE THERAPEUTICS INC stock?
JNCE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does JOUNCE THERAPEUTICS INC belong to?
JOUNCE THERAPEUTICS INC (JNCE) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for JOUNCE THERAPEUTICS INC?
The Revenue of JOUNCE THERAPEUTICS INC (JNCE) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is JOUNCE THERAPEUTICS INC worth?
JOUNCE THERAPEUTICS INC (JNCE) has a market capitalization of 98.95M USD. This makes JNCE a Micro Cap stock.